金日品牌怎么样 申请店铺

我要投票 金日在燕窝行业中的票数:6 更新时间:2024-11-23
金日是哪个国家的品牌?「金日」是金日制药(中国)有限公司旗下著名品牌。该品牌发源于福建,由创始人李冠华在1991期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
金日怎么样

金日,是一家有二十多年历史,集制药、医疗、保健、金融、贸易、房地产为一体的多元化实业集团,拥有香港及内地十几家下属企业,并在新加坡、加拿大等地进行各类投资贸易活动.已在国内厦门、福州、顺德、深圳等地设立制造基地,总投资已达10亿元人民币.1986年,公司开始在中国内地生产“金日牌”系列医药保健品.集团全资子公司“厦门金日制药有限公司”创办于1991年,现拥有口服液、片剂、胶囊剂、颗粒剂、凝膏剂、浸膏剂、乳膏剂、巴布膏剂、膜剂等9条符合国际药品GMP标准的生产线,是福建省最具规模的整体通过国家药品GMP认证的现代化制药企业.

20多年的品牌建设,已使“金日牌”系列产品享誉海内外,“金日牌”洋参已成为中国洋参行业知名品牌,,被誉为东南亚“西洋参之王”;“金日心源素”已成为中国心脑保健第一品牌.公司的发展历程得到了李瑞环、万里、杨成武、王光英、王兆国、钱伟长、万国权、王汉斌、程思远、布赫、吴阶平等党和国家领导人的肯定和赞扬.公司先后被评为厦门外商投资企业二十佳、福建省医药十强、中国保健食品五十强企业、全国百家明星侨资企业,并连续五年纳税超2500万元.

公司不仅拥有历史悠久的品牌、拥有雄厚的资金实力、拥有专业的管理人才、拥有完善的产业化基础、更拥有强大的新产品研发能力.仅在厦门一地就有研发技术人员56人,其中博士研究生1人,硕士5人,高级工程师7人,工程师39人.同时我们还以优越政策积极吸引国内外专家的加入,多年来金日在新产品方面的巨大投入,,吸引了众多国内外医药研究团队,例如中国药科大学中药研究中心、上海第二军医大学临床医学研究中心、上海医药工业研究院制剂工程中心、上海中医药大学、南京中医药大学健康研究中心以及世界卫生组织心血管病研究基地,形成了完美的“产学研”研发模式.

为了实现研发能力的进一步提速和升级,集团决定2007年在厦门建设金日制药二厂,投资人民币2亿多,并争取厦门市政府和国家科技部的支持,用时3-5年在厦门建立一个海西中药现代化工程中心.公司不仅要成为保健品领域的“常青树”,更将致力于打造国际一体化的现代中药产业链.

我们秉承“建一流企业,创一流产品”的宗旨,继续弘扬“诚信求实、开拓创新、锐意进取、奉献社会”的企业精神,不断超越自我,创造新的辉煌.

Jinri is a diversified industrial group with a history of more than 20 years, integrating pharmacy, medical treatment, health care, finance, trade and real estate. It has more than ten subordinate enterprises in Hong Kong and the mainland, and has carried out various investment and trade activities in Singapore, Canada and other places. It has established manufacturing bases in Xiamen, Fuzhou, Shunde, Shenzhen and other places in China, with a total investment of 1 billion yuan in 1986, Xiamen kingri Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the group, was founded in 1991. Now it has 9 production lines that meet the international GMP standards, including oral liquid, tablet, capsule, granule, coagulant, extract, cream, cataplasm, membrane, etc, It is the largest modern pharmaceutical enterprise in Fujian Province that has passed the GMP certification. With more than 20 years of brand building, it has made the "golden day" brand series products famous at home and abroad. The "golden day" brand has become a well-known brand in China's foreign ginseng industry,, Known as the "king of American ginseng" in Southeast Asia, Jinri Xinyuansu has become the first brand of China's heart and brain health care. The company's development process has been affirmed and praised by Li Ruihuan, Wan Li, Yang Chengwu, Wang Guangying, Wang Zhaoguo, Qian Weichang, Wan Guoquan, Wang Hanbin, Cheng Siyuan, BuChE, WuJie equal party and state leaders. The company has been rated as the second foreign-invested enterprise in Xiamen Top 10, top 10 pharmaceutical enterprises in Fujian Province, top 50 health food enterprises in China, top 100 star overseas Chinese enterprises in China, and over 25 million yuan of tax payment for five consecutive years. The company not only has a long history of brand, has a strong financial strength, has professional management personnel, has a sound industrialization foundation, but also has a strong ability of new product research and development. There are research and development technologies in Xiamen alone There are 56 personnel, including 1 doctoral student, 5 Master's degree, 7 senior engineers and 39 engineers. At the same time, we actively attract experts from home and abroad to join us with superior policies. Over the years, Jin RI has invested heavily in new products and attracted many domestic and foreign pharmaceutical research teams, For example, Chinese medicine research center of China Pharmaceutical University, clinical medicine research center of Shanghai Second Military Medical University, preparation engineering center of Shanghai Pharmaceutical Industry Research Institute, Shanghai University of traditional Chinese medicine, health research center of Nanjing University of traditional Chinese medicine and cardiovascular disease research base of World Health Organization, A perfect "production, learning and research" R & D mode has been formed. In order to further speed up and upgrade the R & D capacity, the group decided to build Jinri pharmaceutical No.2 factory in Xiamen in 2007, invest more than 200 million yuan, and strive for the support of Xiamen municipal government and the Ministry of science and technology of the people's Republic of China. In 3-5 years, it will establish a Haixi modern engineering center of traditional Chinese medicine in Xiamen. The company will not only become the "evergreen tree" in the field of health products, We will be committed to building an international integrated modern Chinese medicine industry chain. Adhering to the tenet of "building a first-class enterprise and creating a first-class product", we will continue to carry forward the enterprise spirit of "honesty and truth-seeking, pioneering and innovation, forge ahead with determination and dedication to the society", constantly surpass ourselves and create a new brilliance

本文链接: https://brand.waitui.com/8b9200320.html 联系电话:0592-7220800

千城特选小程序码

7×24h 快讯

上市公司回复可控核聚变概念最新动态:离商用发电还有较长距离

A股可控核聚变概念最近一周走强,东方精工、永鼎股份、弘讯科技等连续涨停。多家上市公司通过公告或互动易平台回复相关问题。①中国广核:公司关注并积极参与先进核能的研发工作,据了解,目前全球可控核聚变研发仍处于科学试验阶段,离实现商用发电还有较长距离。②海陆重工:公司拥有民用核安全设备制造许可证,可以承接核安全2、3的压力容器、热交换器。核聚变能源因其清洁、高效、可持续的特性,被视为解决未来能源危机的理想选择。国家未来的能源规划也明确提出可控核聚变是未来的主要发展方向。公司将抓住行业发展的机会,积极跟进行业动态,努力提高自身装备及技术水平,提高公司竞争力与盈利能力。③盛帮股份:公司核防护业务主要产品为个人穿戴式防护服、核工程类防护装备等。公司立足橡塑高分子材料改性研究,相关产品可应用于可控核聚变领域。④永鼎股份:公司下属控股子公司东部超导主营产品是第二代高温超导带材及超导应用产品,公司不直接生产制造可控核聚变装置,仅为绕制装置的磁体提供材料。目前,东部超导带材产量较少,2023年度营业收入占公司整体收入比重不足1%,且亏损,不会对公司业绩产生重大影响。(财联社)

2小时前

共建广域低空通信网络试验场 上海市通管局与金山区签协议

11月21日,上海市通信管理局与金山区人民政府签署“共同建设广域低空通信网络试验场,打造一体化空天网”战略合作协议。双方将厚植金山全域数字化转型,发挥各自技术和资源优势,围绕支撑低空经济发展、推动区域数字化转型、持续优化营商环境、加强网络和数据安全保障等四个方面进行紧密合作。(e公司)

2小时前

我国首条规模化民航轮胎生产线建成投产

我国首条规模化民航轮胎生产线在广西建成投产,每年可生产10万条高性能民用航空轮胎。(e公司)

2小时前

仲景食品(南阳)有限公司揭牌暨一车间试产运营

据仲景食品消息,11月23日,仲景食品(南阳)有限公司揭牌暨一车间试产仪式举行。南阳产业园一期项目占地184亩,计划建设4个车间,其中一车间主要建设了以上海葱油为代表的调味酱汁类生产线,生产线采取了先进的自动化技术和智能化设备,在生产工艺和质量方面具有显著优势,将大幅提升公司的生产能力,满足日益增长的市场需求。(e公司)

2小时前

知名私募温莎资本被注销登记

中国证券投资基金业协会11月22日公布了多份《纪律处分复核决定书》,部分私募不服纪律处分,向协会提出复核申请,协会均给予复核意见。值得注意的是,知名私募深圳温莎资本管理有限公司,因未及时报告办公地址变更信息、不配合自律检查工作等违规行为,被注销私募管理人登记。厦门京道产业投资基金管理有限公司(以下简称厦门京道)因存在虚假报送投资者信息、在管产品存在非合格投资者的违规事实,被协会公开谴责。(财联社)

2小时前

本页详细列出关于燕之初的品牌信息,含品牌所属公司介绍,燕之初所处行业的品牌地位及优势。
咨询